HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: FDA On Sunscreen Rule; Brazil Bans Most Animal Tests; More

This article was originally published in The Rose Sheet

Executive Summary

FDA’s Spring 2014 Unified Agenda sets a March 2015 estimate for issuing a proposed rule on sunscreen active ingredient safety. More news in brief.

You may also be interested in...

Cosmetics News In Brief: Henkel Caps Pro Hair-Care M&A Spree With Shiseido Deal; Revlon's Q3; More

Henkel's latest pro hair-care acquisition, Shiseido's North American-focused Zotos business, boosts its regional market share ahead of former leader Coty. Meanwhile, Revlon reports "disappointing" third-quarter results, and market researcher NPD trumpets the return to growth of "age specialist" skin-care products.

Coty’s TJoy Unit Continues To Disappoint, Driving $253.3 Mil. Loss In Q3

Coty Inc. recorded a $316.9 million asset write-down in the third fiscal quarter related to its TJoy skin-care business in China, driving a $253.3 million loss overall. The firm will reorganize its mass-market business in the country to improve profitability in Skin & Body Care, which booked an 8% increase in global revenues on the strength of the firm’s philosophy brand, among other highlights, despite TJoy’s drag on the segment’s performance.

Sanofi Bets Big On IO With Synthorx Buy

The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts